Acute administration of corticoids: a new and peculiar stimulus of growth hormone secretion in man.

It is widely accepted that chronic administration of corticoids in man inhibits the GH response to all of the stimuli tested so far. To study the action of corticoids administered acutely, several dexamethasone challenge tests were performed, after which GH levels were measured for 7 h. In eight volunteers, administration of 4 mg dexamethasone (Dex), iv, induced a clear-cut GH release compared with saline administration. The secretion followed an unusual pattern; basal GH levels (1.5 +/- 0.1 micrograms/L) started rising 2 h after Dex injection, reaching a peak of 17.5 +/- 4.4 micrograms/L after 3 or 3.5 h. Peak levels were maintained until 5 h post-Dex and decreased thereafter. Similar data were obtained when Dex was administered to five volunteers at the dose of 8 mg, orally, with a 30-min delay of the GH peak (19.6 +/- 7.9 micrograms/L). To study whether there was a cholinergic input responsible for the Dex action, another group of eight volunteers underwent three Dex tests (4 mg, iv) on three occasions, followed 90 min later by the administration of placebo (control), atropine (0.5 mg, iv), or pyridostigmine (120 mg, orally). The Dex-induced GH peak (20.8 +/- 5.2 micrograms/L) was not significantly increased by pyridostigmine (cholinergic agonist) treatment (24.2 +/- 4.0 micrograms/L). The blockade of muscarinic receptors by atropine induced a delay in the Dex-induced secretory peak, which appeared at 5 h. However, the Dex-atropine GH peak (14.9 +/- 4.1 micrograms/L) was not different from the Dex-placebo one. In conclusion, Dex alone is able to induce a clear-cut GH secretion in man. The stimulus followed a peculiar time pattern, with peaks levels attained 3 h after either iv or oral administration.

[1]  B. Burguera,et al.  Activation of cholinergic neurotransmission by pyridostigmine reverses the inhibitory effect of hyperglycemia on growth hormone (GH) releasing hormone-induced GH secretion in man: does acute hyperglycemia act through hypothalamic release of somatostatin? , 1989, Neuroendocrinology.

[2]  F. Cordido,et al.  Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity. , 1989, The Journal of clinical endocrinology and metabolism.

[3]  C. Diéguez,et al.  GROWTH HORMONE NEUROREGULATION AND ITS ALTERATIONS IN DISEASE STATES , 1988, Clinical endocrinology.

[4]  J. Baxter,et al.  Glucocorticoid control of rat growth hormone gene expression: effect on cytoplasmic messenger ribonucleic acid production and degradation. , 1987, Molecular endocrinology.

[5]  A. Grossman,et al.  GH FEEDBACK OCCURS THROUGH MODULATION OF HYPOTHALAMIC SOMATOSTATIN UNDER CHOLINERGIC CONTROL: STUDIES WITH PYRIDOSTIGMINE AND GHRH , 1987, Clinical endocrinology.

[6]  E. Ghigo,et al.  Potentiation of cholinergic tone by pyridostigmine bromide re-instates and potentiates the growth hormone responsiveness to intermittent administration of growth hormone-releasing factor in man. , 1986, Acta endocrinologica.

[7]  K. Nakagawa,et al.  Effect of dexamethasone on growth hormone (GH) response to growth hormone releasing hormone in acromegaly. , 1985, The Journal of clinical endocrinology and metabolism.

[8]  G. Delitala,et al.  Participation of cholinergic muscarinic receptors in glucagon- and arginine-mediated growth hormone secretion in man. , 1982, The Journal of clinical endocrinology and metabolism.

[9]  P. Seeburg,et al.  Regulation of growth hormone messenger RNA by thyroid and glucocorticoid hormones. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[10]  K. Mashimo,et al.  Suppressibility of plasma growth hormone levels in acromegaly with dexamethasone and phentolamine. , 1973, The Journal of clinical endocrinology and metabolism.

[11]  K. Mashimo,et al.  Suppression of Exercise-Induced Growth Hormone Release with Dexamethasone , 1973, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[12]  S. Hane,et al.  Suppression of the Hypothalamo-Pituitary-Adrenal Axis and Growth Hormone Release with Dexamethasone , 1971, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[13]  W. Bridson,et al.  Cortisol stimulation of growth hormone production by monkey adenohypophysis in tissue culture. , 1968, Biochemical and biophysical research communications.

[14]  A. Frantz,et al.  HUMAN GROWTH HORMONE. CLINICAL MEASUREMENT, RESPONSE TO HYPOGLYCEMIA AND SUPPRESSION BY CORTICOSTEROIDS. , 1964 .

[15]  M. Hartog,et al.  EFFECT OF CORTICOSTEROIDS ON SERUM GROWTH HORMONE. , 1964, Lancet.

[16]  D. Iezzoni,et al.  Effects of prolonged cortisone therapy on the statural growth, skeletal maturation and metabolic status of children. , 1956, The New England journal of medicine.

[17]  B. Burguera,et al.  Depending on the time of administration, dexamethasone potentiates or blocks growth hormone-releasing hormone-induced growth hormone release in man. , 1988, Neuroendocrinology.

[18]  A. Schally,et al.  Atropine blockade of growth hormone (GH)-releasing hormone-induced GH secretion in man is not exerted at pituitary level. , 1986, The Journal of clinical endocrinology and metabolism.

[19]  H. Nakabayashi,et al.  Suppressive effect of glucocorticoid on arginine-induced growth hormone release in normal subjects. , 1974, Steroids and lipids research.

[20]  D. Krieger,et al.  Growth hormone and cortisol responsiveness in Cushing's syndrome. Relation to a possible central nervous system etiology. , 1972, The American journal of medicine.